bioRxivPharmacology & ToxicologyPreprint
Large library docking for cannabinoid-1 receptor agonists with reduced side effects
T. A. Tummino, C. Iliopoulos-Tsoutsouvas, J. M. Braz, E. S. O'Brien, R. M. Stein, V. Craik, N. K. Tran, S. Ganapathy, F. Liu, Y. Shiimura, F. Tong, T. C. Ho, D. S. Radchenko, Y. S. Moroz, S. R. Rosado, K. Bhardwaj, J. Benitez, Y. Liu, H. Kandasamy, C. Normand, M. Semache, L. Sabbagh, I. Glenn, J. J. Irwin, K. K. Kumar, , B. K. Shoichet
Abstract
Large library docking can reveal unexpected chemotypes that complement the structures of biological targets. Seeking new agonists for the cannabinoid-1 receptor (CB1R), we docked 74 million tangible molecules, prioritizing 46 high ranking ones for de novo synthesis and testing. Nine were active by radioligand competition, a 20% hit-rate. Structure-based optimization of one of the most potent of these (Ki = 0.7 {micro}M) led to 4042, a 1.9 nM ligand and a full CB1R agonist. A cryo-EM structure of the purified enantiomer of 4042 ( 1350) in complex with CB1R-Gi1 confirmed its docked pose. The new agonist was strongly analgesic, with generally a 5-10-fold therapeutic window over sedation and catalepsy and no observable conditioned place preference. These findings suggest that new cannabinoid chemotypes may disentangle characteristic cannabinoid side-effects from their analgesia, supporting the further development of cannabinoids as pain therapeutics.
- organism: human
- assay: structural biology
- research focus: drug response / drug discovery
- approach: deep learning
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Library docking for Cannabinoid-2 Receptor ligands
Moira M. Rachman, Christos Iliopoulos‐Tsoutsouvas, … Brian K. Shoichet·Journal of Medicinal ChemistryPeer-reviewed·Jul 3, 2026
- Why does Δ9-Tetrahydrocannabinol act as a partial agonist of cannabinoid receptors?
- Synthesis and pharmacological characterization of UVI3502, a novel cannabinoid receptor 1 (CB1) antagonist/inverse agonist
Iker Bengoetxea de Tena, Gorka Pereira‐Castelo, … Rafael Rodríguez‐Puertas·ACS OmegaPeer-reviewed·Jun 2, 2025
- Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects
Seth F. Vigneron, Shohei Ohno, … Brian K. Shoichet·bioRxiv·Jan 9, 2025
- Integrated pharmacological and structural profiling reveals CB1 residue interaction patterns associated with synthetic cannabinoid receptor agonist efficacy
Hyeokjun Kwon, Chul Kyu Lee, … Jaesuk Yun·bioRxiv·Sep 15, 2026
- Efficacy profiling of structurally diverse cannabinoid receptor ligands across transducer-coupling assays
Soo Jung Oh, Christopher Lucaj, … Hideaki Yano·bioRxiv·Oct 2, 2026